Physician approaches to antithrombotic therapies for recently symptomatic carotid stenosis

HIGHLIGHTS

SUMMARY

Carotid atherosclerosis causes 15-20% of ischemic stroke and transient ischemic attacks (TIAs)1,2 and is associated with high risk of early recurrent stroke, especially in the first few days. Whereas the evidence for secondary prevention of stroke with antithrombotic agents is well established, there remains a paucity of rigorous evidence for the optimal antithrombotic regimen for patients with symptomatic carotid artery stenosis ("hot carotid"). The POINT (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke) and CHANCE (Clopidogrel in High-risk patients with Acute Nondisabling Cerebrovascular Events) trials showed a reduction . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.